Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002611 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer
A Phase 3 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,031
- Enrollment target
NCT00002611: Completed Phase 3 study, sponsored by Children's Oncology Group.
NCT00002611 is a Phase 3 study that has completed, run by Children's Oncology Group. The registered enrollment target is 3,031 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (293% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002611, a Phase 3 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,031 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. It is not yet known whether combination chemotherapy alone or combination chemotherapy plus radiation therapy is more effective for childhood kidney cancer. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy with or without radiation therapy in treating children who have kidney cancer.
Interventions
- DRUG cyclophosphamide
- DRUG etoposide
- BIOLOGICAL filgrastim
- DRUG doxorubicin hydrochloride
- BIOLOGICAL dactinomycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,031 participants |
| Start Date | 1995-07 |
| Est. Completion | 2003-08 |
| Phase | Phase 3 |
What the finished NCT00002611 record still lists
NCT00002611 is an interventional study that assigns participants to a tested intervention. Its 3,031 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (293% higher).
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00002611 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002611 about?
NCT00002611 is a clinical study titled "Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. It is not yet known whether combination chemotherapy alone or combination chemotherapy plus radiation therapy is mo...
What is the current status of trial NCT00002611?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,031 participants. The study started on 1995-07. Estimated completion is 2003-08.
What interventions are being tested in trial NCT00002611?
The interventions under investigation include: cyclophosphamide (DRUG), etoposide (DRUG), filgrastim (BIOLOGICAL), doxorubicin hydrochloride (DRUG), dactinomycin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002611?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002611's enrollment target sits among peer trials
3,031 79th of 2000 higher than 1,922 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07116967 · 3,040 participants · Phase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia